Evidence map›Paper›PMID 36322562›Full record

Trial reportPloS one2022

The effects of reduced nicotine content cigarettes on biomarkers of nicotine and toxicant exposure, smoking behavior and psychiatric symptoms in smokers with mood or anxiety disorders: A double-blind randomized trial.

Jonathan Foulds, Susan Veldheer, Gladys Pachas, Shari Hrabovsky, Ahmad Hameed, Sophia I Allen, Corinne Cather, Nour Azzouz, Jessica Yingst, Erin Hammett and 11 more

Registry-linked trialAbstract readRandomized Controlled Trial
In one paragraph

Trial report in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01928758 (Reduced Nicotine Cigarettes in Smokers With Mood and Anxiety Disorders), which is not on this map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01928758 nacompletednot on this map

Reduced Nicotine Cigarettes in Smokers With Mood and Anxiety Disorders

TypeinterventionalSponsorMilton S. Hershey Medical CenterRan2015 to 2018Enrolled245ConditionsTobacco DependenceArmsReduced Nicotine Content Cigarettes, Usual Nicotine Content Cigarettes
3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Article
  7. Article
  8. E-Liquid Flavor Availability Significantly Affects Cigarette and E-Liquid Purchasing in an Experimental Marketplace Simulating a Low Nicotine Product Standard.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2025
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Jonathan FouldsPenn State Center for Research on Tobacco and Health, Department of Public Health Sciences, Pennsylvania State University-College of Medicine, University Drive, Hershey, PA, United States of America.ORCID 0000-0003-2296-0726
Susan VeldheerPenn State Center for Research on Tobacco and Health, Department of Public Health Sciences, Pennsylvania State University-College of Medicine, University Drive, Hershey, PA, United States of America.
Gladys PachasCenter for Addiction Medicine, Department of Psychiatry, Massachusetts General Hospital, Boston, MA, United States of America.
Shari HrabovskyPenn State Center for Research on Tobacco and Health, Department of Public Health Sciences, Pennsylvania State University-College of Medicine, University Drive, Hershey, PA, United States of America.
Ahmad HameedDepartment of Psychiatry, Pennsylvania State University-College of Medicine, Hershey, PA, United States of America.
Sophia I AllenPenn State Center for Research on Tobacco and Health, Department of Public Health Sciences, Pennsylvania State University-College of Medicine, University Drive, Hershey, PA, United States of America.
Corinne CatherCenter for Addiction Medicine, Department of Psychiatry, Massachusetts General Hospital, Boston, MA, United States of America.
Nour AzzouzCenter for Addiction Medicine, Department of Psychiatry, Massachusetts General Hospital, Boston, MA, United States of America.
Jessica YingstPenn State Center for Research on Tobacco and Health, Department of Public Health Sciences, Pennsylvania State University-College of Medicine, University Drive, Hershey, PA, United States of America.
Erin HammettPenn State Center for Research on Tobacco and Health, Department of Public Health Sciences, Pennsylvania State University-College of Medicine, University Drive, Hershey, PA, United States of America.
Jennifer ModestoPenn State Center for Research on Tobacco and Health, Department of Public Health Sciences, Pennsylvania State University-College of Medicine, University Drive, Hershey, PA, United States of America.
Nicolle M KrebsPenn State Center for Research on Tobacco and Health, Department of Public Health Sciences, Pennsylvania State University-College of Medicine, University Drive, Hershey, PA, United States of America.
Courtney LesterPenn State Center for Research on Tobacco and Health, Department of Public Health Sciences, Pennsylvania State University-College of Medicine, University Drive, Hershey, PA, United States of America.
Neil TrushinPenn State Center for Research on Tobacco and Health, Department of Public Health Sciences, Pennsylvania State University-College of Medicine, University Drive, Hershey, PA, United States of America.
Lisa ReinhartPenn State Center for Research on Tobacco and Health, Department of Public Health Sciences, Pennsylvania State University-College of Medicine, University Drive, Hershey, PA, United States of America.
Emily WassermanPenn State Center for Research on Tobacco and Health, Department of Public Health Sciences, Pennsylvania State University-College of Medicine, University Drive, Hershey, PA, United States of America.
Junjia ZhuPenn State Center for Research on Tobacco and Health, Department of Public Health Sciences, Pennsylvania State University-College of Medicine, University Drive, Hershey, PA, United States of America.
Jason LiaoPenn State Center for Research on Tobacco and Health, Department of Public Health Sciences, Pennsylvania State University-College of Medicine, University Drive, Hershey, PA, United States of America.
Joshua E MuscatPenn State Center for Research on Tobacco and Health, Department of Public Health Sciences, Pennsylvania State University-College of Medicine, University Drive, Hershey, PA, United States of America.
John P RichiePenn State Center for Research on Tobacco and Health, Department of Public Health Sciences, Pennsylvania State University-College of Medicine, University Drive, Hershey, PA, United States of America.
A Eden EvinsCenter for Addiction Medicine, Department of Psychiatry, Massachusetts General Hospital, Boston, MA, United States of America.

Funding

Research Training and Educational Component (Component I) p370-385P50DA036107 · NIDA · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI FOULDS, JONATHAN, MUSCAT, JOSHUA E · 2013 to 2018
$19.5M
Penn State Clinical and Translational Science InstituteUL1TR000127 · NCATS · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI SINOWAY, LAWRENCE I · 2012 to 2015
$17.1M
NCATS NIH HHS UL1 TR000127NIDA NIH HHS P50 DA036107
6 · The paper itself

Abstract

backgroundThe U.S. Food and Drug Administration and the government of New Zealand have proposed a reduction of the nicotine content in cigarettes to very low levels. This study examined the potential effects of this regulation in smokers with affective disorders.

methodsIn a randomized controlled parallel group trial conducted at two sites in the USA (Penn State University, Hershey, PA and Massachusetts General Hospital, Boston, MA) 188 adult smokers with a current (n = 118) or lifetime (n = 70) anxiety or unipolar mood disorder, not planning to quit in the next 6 months, were randomly assigned (1:1) to smoke either Usual Nicotine Content (UNC) (11.6 mg nicotine/cigarette) research cigarettes, or Reduced Nicotine Content (RNC) research cigarettes where the nicotine content per cigarette was progressively reduced to 0.2 mg in five steps over 18 weeks. Participants were then offered the choice to either receive assistance to quit smoking, receive free research cigarettes, or resume using their own cigarette brand during a 12-week follow-up period. Main outcomes were biomarkers of nicotine and toxicant exposure, smoking behavior and dependence and severity of psychiatric symptoms. The pre-registered primary outcome was plasma cotinine.

resultsA total of 143 (76.1%) randomized participants completed the randomized phase of the trial, 69 (73.4%) in the RNC group and 74 (78.8%) in the UNC group. After switching to the lowest nicotine content cigarettes, compared to smokers in the UNC group, at the last randomized visit the RNC group had significantly lower plasma cotinine (metabolite of nicotine): difference between groups, -175.7, 95% CI [-218.3, -133.1] ng/ml. Urine NNAL (metabolite of NNK, a lung carcinogen), exhaled carbon-monoxide, cigarette consumption, and cigarette dependence were also significantly lower in the RNC group than the UNC group. No between-group differences were found on a range of other biomarkers (e.g. 8-isoprostanes) or health indicators (e.g. blood pressure), or on 5 different psychiatric questionnaires, including the Kessler K6 measure of psychological distress. At the end of the subsequent 12-week treatment choice phase, those randomized to the RNC group were more likely to have quit smoking, based on initial intent-to-treat sample, n = 188 (18.1% RNC v 4.3% UNC, p = 0.004).

conclusionReducing nicotine content in cigarettes to very low levels reduces some toxicant exposures and cigarette addiction and increases smoking cessation in smokers with mood and/or anxiety disorders, without worsening mental health.

trial registrationTRN: NCT01928758, registered August 21, 2013.

Indexed as

NicotineTobacco ProductsAdultAnxiety DisordersBiomarkersCotinineHazardous SubstancesHumansSmokersSmokingBiomarkersCotinineHazardous SubstancesNicotine

Identifiers

PMID36322562
PMCPMC9629593

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.